Study Focus: This research is to find out how well a new medication called LB-102 works for adults with sudden worsening of schizophrenia. Schizophrenia is a serious mental disorder affecting how a person thinks, feels, and behaves.

Study Details: This is a Phase 3 study, which means the drug has already been tested in earlier phases for safety. In this study, participants receive either LB-102 or a placebo (a pill that looks like the medicine but doesn’t have the active drug). The study is "double-blind," meaning neither the participants nor the doctors know who gets the actual drug, ensuring unbiased results.

• Participants must stay in the hospital for the study duration.
• Eligibility includes a Body Mass Index (BMI) between 18 and 40 and specific scores on a test called PANSS.
• Those with certain medical conditions or risks, like heart disease or history of violent behavior, cannot participate.

This study aims to test the effectiveness and safety of LB-102, and results may help improve treatments for schizophrenia. Participants contribute to important medical research and receive careful monitoring throughout the study.